Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0320216 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Jillian M Rung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Enterprise Analytics, Highmark Health, Pittsburgh, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Biphenyl Compounds, Valsartan, Aminobutyrates, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
The goals of this retrospective cohort analysis were to determine real-world dose and titration patterns of sacubitril/valsartan (SAC/VAL), a heart failure medication, and examine whether dose patterns are associated with healthcare utilization and costs.
Methods
Adult health plan members (18-100 years old) who initiated SAC/VAL between 2020 and 2022 and had continuous enrollment 6 months prior to, and at least 3 months following SAC/VAL initiation were identified. Members also had to have 3 months of SAC/VAL fills with good adherence ( N = 2,977). Claims data were used to characterize dosage patterns and compare total costs of care, as well as all-cause and heart failure- hospital admissions across those with different terminal SAC/VAL doses.
Results
Most members initiated SAC/VAL at the lowest dose (76%, n = 2,267), of whom few titrated upward by their final fill (31%, n = 703). Overall, only 19% ( n = 563) were at target by their final fill. Those ending on higher doses experienced significantly fewer all-cause admissions (incidence rate ratios of 1.52 [ SE = .16] to 2.66 [ SE = .37]; p s < .001) and incurred significantly lower total costs of care while on SAC/VAL (cost ratios of 1.21 [ SE = .06] to 1.48 [ SE = .09]; p s < .001).
Conclusion
Most individuals initiate and remain on the lowest SAC/VAL dose despite guidelines to titrate upward. SAC/VAL dosage is significantly associated with outcomes, with higher doses associated with more clinical and cost benefits. Research is needed to identify barriers to dose titration and to develop interventions for maximal patient benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Enterprise Analytics, Highmark Health, Pittsburgh, Pennsylvania, United States of America.
- Allegheny Health Network, Pittsburgh, Pennsylvania, United States of America.
- Allegheny General Hospital, Pittsburgh, Pennsylvania, United States of America.
- Penn State Health, Hershey, Pennsylvania, United States of America.
- Penn State University, University Park, Pennsylvania, United States of America.
ORCID-Profile: Jillian M Rung, Tyson S Barrett
Zitieren
APA
Rung, J. M., Barrett, T. S., LeJeune, K., Richards, S. B., Raina, A., & Sinoway, L. (2025). Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0320216
Vancouver
Rung JM, Barrett TS, LeJeune K, Richards SB, Raina A, Sinoway L. Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. PLOS ONE. 2025. doi:10.1371/journal.pone.0320216
BibTeX
@article{Rung2025,
author = {Rung, Jillian M and Barrett, Tyson S and LeJeune, Keith and Richards, Shannon B and Raina, Amresh and Sinoway, Lawrence},
title = {Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0320216}
}
EUVIMED